Victor Golmer
BNT327, a bispecific antibody candidate under development by BioNTech (NASDAQ:BNTX) that is seen as critical to the biotech’s future success, will compete favorably against rival Summit Therapeutics’ (NASDAQ:SMMT) ivonescimab, according to a BioNTech exec.
Speaking at the FT Live US